Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in: Targeted Oncology 4/2015

01-12-2015 | Review

Aptamer-Functionalized Nanoparticles as “Smart Bombs”: The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment

Authors: Gregory Benedetto, C. Greer Vestal, Christine Richardson

Published in: Targeted Oncology | Issue 4/2015

Login to get access

Abstract

Conventional delivery of chemotherapeutic agents leads to multiple systemic side effects and toxicity, limiting the doses that can be used. The development of targeted therapies to selectively deliver anti-cancer agents to tumor cells without damaging neighboring unaffected cells would lead to higher effective local doses and improved response rates. Aptamers are single-stranded oligonucleotides that bind to target molecules with both high affinity and high specificity. The high specificity exhibited by aptamers promotes localization and uptake by specific cell populations, such as tumor cells, and their conjugation to anti-cancer drugs has been explored for targeted therapy. Advancements in the development of polymeric nanoparticles allow anti-cancer drugs to be encapsulated in protective nonreactive shells for controlled drug delivery with reduced toxicity. The conjugation of aptamers to nanoparticle-based therapeutics may further enhance direct targeting and personalized medicine. Here we present how the combinatorial use of aptamer and nanoparticle technologies has the potential to develop “smart bombs” for targeted cancer treatment, highlighting recent pre-clinical studies demonstrating efficacy for the direct targeting to particular tumor cell populations. However, despite these pre-clinical promising results, there has been little progress in moving this technology to the bedside.
Literature
1.
2.
Chen AC, Migliaccio I, Rimawi M, Lopez-Tarruella S, Creighton CJ, Massarweh S, Huang C, Wang YC, Batra SK, Gutierrez MC, Osborne CK, Schiff R (2012) Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. Breast Cancer Res Treat 134(2):583–593. doi:10.​1007/​s10549-012-2082-9 PubMedCentralPubMedCrossRef
3.
Brody EN, Gold L (2000) Aptamers as therapeutic and diagnostic agents. J Biotechnol 74(1):5–13PubMed
4.
Datta J, Xu S, Rosemblit C, Smith JB, Cintolo JA, Powell D Jr, Czerniecki BJ (2015) CD4+ T-helper type 1 cytokines and trastuzumab facilitate CD8+ T-cell targeting of HER-2/neu-expressing cancers. Cancer Immunol Res. doi:10.​1158/​2326-6066.​CIR-14-0208 PubMed
5.
6.
7.
Jayasena SD (1999) Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 45(9):1628–1650PubMed
8.
9.
10.
11.
12.
13.
14.
Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249(4968):505–510PubMedCrossRef
15.
16.
17.
18.
19.
Xiao Z, Levy-Nissenbaum E, Alexis F, Luptak A, Teply BA, Chan JM, Shi J, Digga E, Cheng J, Langer R, Farokhzad OC (2012) Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection. ACS Nano 6(1):696–704. doi:10.​1021/​nn204165v PubMedCentralPubMedCrossRef
20.
21.
22.
23.
24.
Zhu G, Ye M, Donovan MJ, Song E, Zhao Z, Tan W (2012) Nucleic acid aptamers: an emerging frontier in cancer therapy. Chem Commun (Camb) 48(85):10472–10480. doi:10.​1039/​c2cc35042d CrossRef
25.
26.
Esposito CL, Catuogno S, de Franciscis V, Cerchia L (2011) New insight into clinical development of nucleic acid aptamers. Discov Med 11(61):487–496PubMed
27.
28.
29.
Healy JM, Lewis SD, Kurz M, Boomer RM, Thompson KM, Wilson C, McCauley TG (2004) Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm Res 21(12):2234–2246PubMedCrossRef
30.
31.
32.
33.
34.
35.
36.
Burmeister PE, Lewis SD, Silva RF, Preiss JR, Horwitz LR, Pendergrast PS, McCauley TG, Kurz JC, Epstein DM, Wilson C, Keefe AD (2005) Direct in vitro selection of a 2′-O-methyl aptamer to VEGF. Chem Biol 12(1):25–33. doi:10.​1016/​j.​chembiol.​2004.​10.​017
37.
Jellinek D, Green LS, Bell C, Lynott CK, Gill N, Vargeese C, Kirschenheuter G, McGee DP, Abesinghe P, Pieken WA et al (1995) Potent 2′-amino-2′-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. Biochemistry 34(36):11363–11372PubMedCrossRef
38.
Lin Y, Nieuwlandt D, Magallanez A, Feistner B, Jayasena SD (1996) High-affinity and specific recognition of human thyroid stimulating hormone (hTSH) by in vitro-selected 2′-amino-modified RNA. Nucleic Acids Res 24(17):3407–3414PubMedCentralPubMedCrossRef
39.
40.
41.
42.
43.
Weiss S, Proske D, Neumann M, Groschup MH, Kretzschmar HA, Famulok M, Winnacker EL (1997) RNA aptamers specifically interact with the prion protein PrP. J Virol 71(11):8790–8797PubMedCentralPubMed
44.
45.
Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Patel M (2006) Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 113(9):1508 e1501–1525. doi:10.​1016/​j.​ophtha.​2006.​02.​064
46.
Obubuafo A, Balamurugan S, Shadpour H, Spivak D, McCarley RL, Soper SA (2008) Poly(methyl methacrylate) microchip affinity capillary gel electrophoresis of aptamer-protein complexes for the analysis of thrombin in plasma. Electrophoresis 29(16):3436–3445. doi:10.​1002/​elps.​200700854 PubMedCrossRef
47.
48.
He K, Porter KW, Hasan A, Briley J, Shaw BR (1999) Synthesis of 5-substituted 2′-deoxycytidine 5′-(alpha-P-borano)triphosphates, their incorporationinto DNA and effects on exonuclease. Nucleic Acids Res 27(8):1788–1794
49.
50.
51.
Bundgaard Jensen TB, Pasternak A, Madsen AS, Petersen M, Wengel J (2011) Synthesis and structural characterization of 2 ′-fluoro-alpha-L-RNA-modified oligonucleotides. Chembiochem 12(12):1903–1910. doi:10.​1002/​cbic.​201100161 CrossRef
52.
53.
Schmidt KS, Borkowski S, Kurreck J, Stephens AW, Bald R, Hecht M, Friebe M, Dinkelborg L, Erdmann VA (2004) Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucleic Acids Res 32(19):5757–5765. doi:10.​1093/​nar/​gkh862 PubMedCentralPubMedCrossRef
54.
55.
Singh SK, Kumar R, Wengel J (1998) Synthesis of novel Bicyclo[2.2.1] ribonucleosides: 2′-Amino- and 2′-thio-LNA monomeric nucleosides. J Org Chem 63(18):6078–6079PubMedCrossRef
56.
Petersen M, Bondensgaard K, Wengel J, Jacobsen JP (2002) Locked nucleic acid (LNA) recognition of RNA: NMR solution structures of LNA: RNA hybrids. J Am Chem Soc 124(21):5974–5982. doi:10.​1021/​Ja012288d PubMedCrossRef
57.
Yang X, Fennewald S, Luxon BA, Aronson J, Herzog NK, Gorenstein DG (1999) Aptamers containing thymidine 3′-O-phosphorodithioates: synthesis and binding to nuclear factor-kappaB. Bioorg Med Chem Lett 9(23):3357–3362
58.
59.
Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, Robinson GS, Adamis AP, Shima DT (2006) Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 168(6):2036–2053. doi:10.​2353/​ajpath.​2006.​050588 PubMedCentralPubMedCrossRef
60.
Chelliserrykattil J, Ellington AD (2004) Evolution of a T7 RNA polymerase variant that transcribes 2′-O-methyl RNA. Nat Biotechnol 22(9):1155–1160. doi:10.​1038/​nbt1001
61.
62.
63.
Sheehan JP, Lan HC (1998) Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood 92(5):1617–1625PubMed
64.
Farman CA, Kornbrust DJ (2003) Oligodeoxynucleotide studies in primates: antisense and immune stimulatory indications. Toxicol Pathol 31[Suppl]:119–122PubMed
65.
Henry SP, Bolte H, Auletta C, Kornbrust DJ (1997) Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Toxicology 120(2):145–155PubMedCrossRef
66.
67.
Swayze EE, Siwkowski AM, Wancewicz EV, Migawa MT, Wyrzykiewicz TK, Hung G, Monia BP, Bennett CF (2007) Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res 35(2):687–700. doi:10.​1093/​nar/​gkl1071 PubMedCentralPubMedCrossRef
68.
Hagedorn PH, Yakimov V, Ottosen S, Kammler S, Nielsen NF, Hog AM, Hedtjarn M, Meldgaard M, Moller MR, Orum H, Koch T, Lindow M (2013) Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern. Nucleic Acid Ther 23(5):302–310. doi:10.​1089/​nat.​2013.​0436 PubMedCentralPubMedCrossRef
69.
70.
71.
Henry SP, Giclas PC, Leeds J, Pangburn M, Auletta C, Levin AA, Kornbrust DJ (1997) Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J Pharmacol Exp Ther 281(2):810–816PubMed
72.
Henry SP, Monteith D, Levin AA (1997) Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des 12(5):395–408PubMed
73.
74.
75.
Du KL, Mick R, Busch TM, Zhu TC, Finlay JC, Yu G, Yodh AG, Malkowicz SB, Smith D, Whittington R, Stripp D, Hahn SM (2006) Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer. Lasers Surg Med 38(5):427–434. doi:10.​1002/​lsm.​20341 PubMedCrossRef
76.
Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331(22):1480–1487. doi:10.​1056/​NEJM199412013312​203 PubMedCrossRef
77.
78.
79.
80.
Hector A, Montgomery EA, Karikari C, Canto M, Dunbar KB, Wang JS, Feldmann G, Hong SM, Haffner MC, Meeker AK, Holland SJ, Yu J, Heckrodt TJ, Zhang J, Ding P, Goff D, Singh R, Roa JC, Marimuthu A, Riggins GJ, Eshleman JR, Nelkin BD, Pandey A, Maitra A (2010) The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol Ther 10(10):1009–1018. doi:10.​4161/​cbt.​10.​10.​13248 PubMedCrossRef
81.
Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, Duan M, Torneros A, Yu J, Heckrodt TJ, Zhang J, Ding P, Apatira A, Chua J, Brandt R, Pine P, Goff D, Singh R, Payan DG, Hitoshi Y (2010) R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 70(4):1544–1554. doi:10.​1158/​0008-5472.​CAN-09-2997 PubMedCrossRef
82.
Ye X, Li Y, Stawicki S, Couto S, Eastham-Anderson J, Kallop D, Weimer R, Wu Y, Pei L (2010) An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29(38):5254–5264. doi:10.​1038/​onc.​2010.​268 PubMedCrossRef
83.
84.
85.
Strand J, Varasteh Z, Eriksson O, Abrahmsen L, Orlova A, Tolmachev V (2014) Gallium-68-labeled affibody molecule for PET imaging of PDGFRbeta expression in vivo. Mol Pharm 11(11):3957–3964. doi:10.​1021/​mp500284t PubMedCrossRef
86.
Camorani S, Esposito CL, Rienzo A, Catuogno S, Iaboni M, Condorelli G, de Franciscis V, Cerchia L (2014) Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRbeta aptamer. Mol Ther 22(4):828–841. doi:10.​1038/​mt.​2013.​300 PubMedCentralPubMed
87.
Biesecker G, Dihel L, Enney K, Bendele RA (1999) Derivation of RNA aptamer inhibitors of human complement C5. Immunopharmacology 42(1–3):219–230PubMedCrossRef
88.
Ackroyd R, Kelty CJ, Brown NJ, Stephenson TJ, Stoddard CJ, Reed MW (2003) Eradication of dysplastic Barrett’s oesophagus using photodynamic therapy: long-term follow-up. Endoscopy 35(6):496–501. doi:10.​1055/​s-2003-39676 PubMedCrossRef
89.
Cuenca RE, Allison RR, Sibata C, Downie GH (2004) Breast cancer with chest wall progression: treatment with photodynamic therapy. Ann Surg Oncol 11(3):322–327PubMedCrossRef
90.
91.
92.
93.
Tang Z, Shangguan D, Wang K, Shi H, Sefah K, Mallikratchy P, Chen HW, Li Y, Tan W (2007) Selection of aptamers for molecular recognition and characterization of cancer cells. Anal Chem 79(13):4900–4907. doi:10.​1021/​ac070189y PubMedCrossRef
94.
95.
96.
97.
Liu Q, Xu L, Zhang X, Li N, Zheng J, Guan M, Fang X, Wang C, Shu C (2013) Enhanced photodynamic efficiency of an aptamer-guided fullerene photosensitizer toward tumor cells. Chem Asian J 8(10):2370–2376. doi:10.​1002/​asia.​201300039
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
Lupold SE, Hicke BJ, Lin Y, Coffey DS (2002) Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 62(14):4029–4033PubMed
111.
Taghdisi SM, Danesh NM, Sarreshtehdar Emrani A, Tabrizian K, Zandkarimi M, Ramezani M, Abnous K (2013) Targeted delivery of epirubicin to cancer cells by PEGylated A10 aptamer. J Drug Target 21(8):739–744. doi:10.​3109/​1061186X.​2013.​812095
112.
113.
Willner D, Trail PA, Hofstead SJ, King HD, Lasch SJ, Braslawsky GR, Greenfield RS, Kaneko T, Firestone RA (1993) (6-Maleimidocaproyl)hydrazone of doxorubicin–a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjug Chem 4(6):521–527PubMedCrossRef
114.
115.
Subramanian N, Raghunathan V, Kanwar JR, Kanwar RK, Elchuri SV, Khetan V, Krishnakumar S (2012) Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer. Mol Vis 18:2783–2795PubMedCentralPubMed
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
Zhu G, Hu R, Zhao Z, Chen Z, Zhang X, Tan W (2013) Noncanonical self-assembly of multifunctional DNA nanoflowers for biomedical applications. J Am Chem Soc 135(44):16438–16445. doi:10.​1021/​ja406115e PubMedCrossRef
126.
127.
Chong CS, Cao M, Wong WW, Fischer KP, Addison WR, Kwon GS, Tyrrell DL, Samuel J (2005) Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J Control Release 102(1):85–99. doi:10.​1016/​j.​jconrel.​2004.​09.​014 PubMedCrossRef
128.
129.
130.
131.
132.
Rouf MA, Vural I, Renoir JM, Hincal AA (2009) Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells. J Liposome Res 19(4):322–331. doi:10.​3109/​0898210090296304​3 PubMedCrossRef
133.
Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenholz Y (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54(4):987–992PubMed
134.
Gabizon A, Isacson R, Libson E, Kaufman B, Uziely B, Catane R, Ben-Dor CG, Rabello E, Cass Y, Peretz T et al (1994) Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol 33(7):779–786PubMedCrossRef
135.
Gabizon AA (1994) Liposomal anthracyclines. Hematol Oncol Clin North Am 8(2):431–450PubMed
136.
137.
138.
Rafiyath SM, Rasul M, Lee B, Wei G, Lamba G, Liu D (2012) Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp. Hematol Oncol 1(1):10. doi:10.​1186/​2162-3619-1-10 CrossRef
139.
Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L, Winer E (2002) Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94(1):25–36. doi:10.​1002/​cncr.​10201 PubMedCrossRef
140.
Hatakeyama H, Akita H, Harashima H (2013) The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biol Pharm Bull 36(6):892–899PubMedCrossRef
141.
Qaddoumi MG, Ueda H, Yang J, Davda J, Labhasetwar V, Lee VH (2004) The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm Res 21(4):641–648PubMedCrossRef
142.
Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R (1994) Biodegradable long-circulating polymeric nanospheres. Science 263(5153):1600–1603PubMedCrossRef
143.
Bege N, Renette T, Jansch M, Reul R, Merkel O, Petersen H, Curdy C, Muller RH, Kissel T (2011) Biodegradable poly(ethylene carbonate) nanoparticles as a promising drug delivery system with “stealth” potential. Macromol Biosci 11(7):897–904. doi:10.​1002/​mabi.​201000496 PubMedCrossRef
144.
145.
Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet 345(8956):1008–1012PubMedCrossRef
146.
Westphal M, Ram Z, Riddle V, Hilt D, Bortey E (2006) Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 148(3):269–275. doi:10.​1007/​s00701-005-0707-z, discussion 275CrossRef
147.
Ran Z, Sun Y, Chang B, Ren Q, Yang W (2013) Silica composite nanoparticles containing fluorescent solid core and mesoporous shell with different thickness as drug carrier. J Colloid Interface Sci 410:94–101. doi:10.​1016/​j.​jcis.​2013.​08.​015
148.
149.
150.
Kwon S, Singh RK, Perez RA, Abou Neel EA, Kim HW, Chrzanowski W (2013) Silica-based mesoporous nanoparticles for controlled drug delivery. J Tissue Eng 4:2041731413503357. doi:10.​1177/​2041731413503357​
151.
Lee JE, Lee N, Kim H, Kim J, Choi SH, Kim JH, Kim T, Song IC, Park SP, Moon WK, Hyeon T (2010) Uniform mesoporous dye-doped silica nanoparticles decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fluorescence imaging, and drug delivery. J Am Chem Soc 132(2):552–557. doi:10.​1021/​ja905793q PubMedCrossRef
152.
153.
154.
Chen C, Geng J, Pu F, Yang X, Ren J, Qu X (2011) Polyvalent nucleic acid/mesoporous silica nanoparticle conjugates: dual stimuli-responsive vehicles for intracellular drug delivery. Angew Chem Int Ed Engl 50(4):882–886. doi:10.​1002/​anie.​201005471 PubMedCrossRef
155.
156.
Wu C, Chen C, Lai J, Chen J, Mu X, Zheng J, Zhao Y (2008) Molecule-scale controlled-release system based on light-responsive silica nanoparticles. Chem Commun (Camb) 23:2662–2664. doi:10.​1039/​b804886j CrossRef
157.
158.
159.
160.
161.
162.
Hernandez FJ, Hernandez LI, Pinto A, Schafer T, Ozalp VC (2013) Targeting cancer cells with controlled release nanocapsules based on a single aptamer. Chem Commun (Camb) 49(13):1285–1287. doi:10.​1039/​c2cc37370j CrossRef
163.
Kim S, Ohulchanskyy TY, Bharali D, Chen Y, Pandey RK, Prasad PN (2009) Organically modified silica nanoparticles with intraparticle heavy-atom effect on the encapsulated photosensitizer for enhanced efficacy of photodynamic therapy. J Phys Chem C Nanomater Interfaces 113:12641–12644. doi:10.​1021/​jp900573s PubMedCentralPubMedCrossRef
164.
165.
Yin J, He X, Wang K, Qing Z, Wu X, Shi H, Yang X (2012) One-step engineering of silver nanoclusters-aptamer assemblies as luminescent labels to target tumor cells. Nanoscale 4(1):110–112. doi:10.​1039/​c1nr11265a PubMedCrossRef
166.
Zhang JQ, Wang YS, Xue JH, He Y, Yang HX, Liang J, Shi LF, Xiao XL (2012) A gold nanoparticles-modified aptamer beacon for urinary adenosine detection based on structure-switching/fluorescence-“turning on” mechanism. J Pharm Biomed Anal 70:362–368. doi:10.​1016/​j.​jpba.​2012.​05.​032 PubMedCrossRef
167.
168.
Zhu Y, Chandra P, Shim YB (2013) Ultrasensitive and selective electrochemical diagnosis of breast cancer based on a hydrazine–Au nanoparticle-aptamer bioconjugate. Anal Chem 85(2):1058–1064. doi:10.​1021/​ac302923k
169.
170.
171.
172.
Maeda H (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41:189–207PubMedCrossRef
173.
174.
175.
176.
177.
Brown SD, Nativo P, Smith JA, Stirling D, Edwards PR, Venugopal B, Flint DJ, Plumb JA, Graham D, Wheate NJ (2010) Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc 132(13):4678–4684. doi:10.​1021/​ja908117a PubMedCentralPubMedCrossRef
178.
179.
180.
181.
Van Lehn RC, Ricci M, Silva PH, Andreozzi P, Reguera J, Voitchovsky K, Stellacci F, Alexander-Katz A (2014) Lipid tail protrusions mediate the insertion of nanoparticles into model cell membranes. Nature Commun 5:4482. doi: 10.​1038/​ncomms5482
182.
183.
184.
185.
Dreher KL (2004) Health and environmental impact of nanotechnology: toxicological assessment of manufactured nanoparticles. Toxicol Sci 77(1):3–5PubMedCrossRef
186.
187.
Shukla R, Bansal V, Chaudhary M, Basu A, Bhonde RR, Sastry M (2005) Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview. Langmuir 21(23):10644–10654. doi:10.​1021/​la0513712 PubMedCrossRef
188.
Du L, Suo S, Wang G, Jia H, Liu KJ, Zhao B, Liu Y (2013) Mechanism and cellular kinetic studies of the enhancement of antioxidant activity by using surface-functionalized gold nanoparticles. Chemistry 19(4):1281–1287. doi:10.​1002/​chem.​201203506 PubMedCrossRef
189.
Chen J, Wang H, Long W, Shen X, Wu D, Song SS, Sun YM, Liu PX, Fan S, Fan F, Zhang XD (2013) Sex differences in the toxicity of polyethylene glycol-coated gold nanoparticles in mice. Int J Nanomedicine 8:2409–2419. doi:10.​2147/​IJN.​S46376 PubMedCentralPubMed
190.
191.
192.
193.
194.
Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D’Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD (2005) A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112(10):1747–1757. doi:10.​1016/​j.​ophtha.​2005.​06.​007 PubMedCrossRef
195.
196.
Guarneri V, Dieci MV, Conte P (2012) Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. Expert Opin Pharmacother 13(3):395–406. doi:10.​1517/​14656566.​2012.​651127 PubMedCrossRef
197.
Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, Nakatomi I, Yokoyama M, Kataoka K, Kakizoe T (2005) NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 92(7):1240–1246. doi:10.​1038/​sj.​bjc.​6602479 PubMedCentralPubMedCrossRef
198.
199.
Ramanathan R, Hamburg SI, Borad M, Seetharam M, Kundranda M, Lee P, Frelund P, Gibert M, Mast C, Semple S, Judge A, Crowell A, Vocila L, MacLachlan I, Northfeld DW (2013) A phase I dose escalation study of TKM-080301, a RNA therapeutic directed aptamer against PLK1, in patients with advanced solid tumors Paper presented at the 104th Annual Meeting of the American Association of Cancer Research., Washington, D.C. J Clin Oncol 31, (suppl; abstr TPS2621)
200.
Zuckerman JE, Gritli I, Tolcher A, Heidel JD, Lim D, Morgan R, Chmielowski B, Ribas A, Davis ME, Yen Y (2014) Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc Natl Acad Sci USA 111(31):11449–11454. doi:10.​1073/​pnas.​1411393111 PubMedCentralPubMedCrossRef
201.
Pottier A, Borghi E, Levy L (2014) New use of metals as nanosized radioenhancers. Anticancer Res 34(1):443–453PubMed
202.
203.
204.
Perche F, Torchilin VP (2013) Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J Drug Del 2013:705265. doi:10.​1155/​2013/​705265
205.
Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC (2011) Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci USA 108(5):1850–1855. doi:10.​1073/​pnas.​1011379108
206.
Zhang K, Sefah K, Tang L, Zhao Z, Zhu G, Ye M, Sun W, Goodison S, Tan W (2012) A novel aptamer developed for breast cancer cell internalization. ChemMedChem 7(1):79–84. doi:10.​1002/​cmdc.​201100457
207.
He X, Hai L, Su J, Wang K, Wu X (2011) One-pot synthesis of sustained-released doxorubicin silica nanoparticles for aptamer targeted delivery to tumor cells. Nanoscale 3(7):2936–2942. doi:10.​1039/​c0nr00913j
208.
Li LL, Xie M, Wang J, Li X, Wang C, Yuan Q, Pang DW, Lu Y, Tan W (2013) A vitamin-responsive mesoporous nanocarrier with DNA aptamer-mediated cell targeting. Chem Commun (Camb) 49(52):5823–5825. doi:10.​1039/​c3cc41072b
209.
Jalalian SH, Taghdisi SM, Shahidi Hamedani N, Kalat SA, Lavaee P, Zandkarimi M, Ghows N, Jaafari MR, Naghibi S, Danesh NM, Ramezani M, Abnous K (2013) Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo. Eur J Pharm Sci 50(2):191–197. doi:10.​1016/​j.​ejps.​2013.​06.​015
210.
Yu C, Hu Y, Duan J, Yuan W, Wang C, Xu H, Yang XD (2011) Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. PLoS ONE 6(9):e24077. doi:10.​1371/​journal.​pone.​0024077
211.
212.
Aravind A, Jeyamohan P, Nair R, Veeranarayanan S, Nagaoka Y, Yoshida Y, Maekawa T, Kumar DS (2012) AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery. Biotechnol Bioeng 109(11):2920–2931. doi:10.​1002/​bit.​24558
213.
Zhang Z, Balogh D, Wang F, Sung SY, Nechushtai R, Willner I (2013) Biocatalytic release of an anticancer drug from nucleic-acids-capped mesoporous SiO2 Using DNA or molecular biomarkers as triggering stimuli. ACS Nano 7(10):8455–8468. doi:10.​1021/​nn403772j
214.
Zhou W, Zhou Y, Wu J, Liu Z, Zhao H, Liu J, Ding J (2014) Aptamer-nanoparticle bioconjugates enhance intracellular delivery of vinorelbine to breast cancer cells. J Drug Target 22(1):57–66. doi:10.​3109/​1061186X.​2013.​839683
215.
Lin Z, Ma Q, Fei X, Zhang H, Su X (2014) A novel aptamer functionalized CuInS2 quantum dots probe for daunorubicin sensing and near infrared imaging of prostate cancer cells. Anal Chim Acta 818:54–60. doi:10.​1016/​j.​aca.​2014.​01.​057
216.
Li L, Hou J, Liu X, Guo Y, Wu Y, Zhang L, Yang Z (2014) Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas. Biomaterials 35(12):3840–3850. doi:10.​1016/​j.​biomaterials.​2014.​01.​019
217.
Sayari E, Dinarvand M, Amini M, Azhdarzadeh M, Mollarazi E, Ghasemi Z, Atyabi F (2014) MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery. Int J Pharm 473(1–2):304–315. doi:10.​1016/​j.​ijpharm.​2014.​05.​041
218.
Shiao YS, Chiu HH, Wu PH, Huang YF (2014) Aptamer-functionalized gold nanoparticles as photoresponsive nanoplatform for Co-drug delivery. ACS Appl Mater Interfaces 6(24):21832–21841. doi:10.​1021/​am5026243
219.
Kolishetti N, Dhar S, Valencia PM, Lin LQ, Karnik R, Lippard SJ, Langer R, Farokhzad OC (2010) Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci USA 107(42):17939–17944. doi:10.​1073/​pnas.​1011368107
220.
Kim E, Jung Y, Choi H, Yang J, Suh JS, Huh YM, Kim K, Haam S (2010) Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials 31(16):4592–4599. doi:10.​1016/​j.​biomaterials.​2010.​02.​030
221.
222.
Prasad P, Cheng J, Shuhendler A, Rauth AM, Wu XY (2012) A novel nanoparticle formulation overcomes multiple types of membrane efflux pumps in human breast cancer cells. Drug Deliv Transl Res 2(2):95–105. doi:10.​1007/​s13346-011-0051-1 PubMedCrossRef
223.
Liu M, Chen D, Wang C, Chen X, Wen Z, Cao Y, He H (2015) Intracellular target delivery of 10-hydroxycamptothecin with solid lipid nanoparticles against multidrug resistance. J Drug Target. 13:1–6. doi:10.​3109/​1061186X.​2015.​1020427
224.
Qiu L, Chen T, Ocsoy I, Yasun E, Wu C, Zhu G, You M, Han D, Jiang J, Yu R, Tan W (2015) A cell-targeted, size-photocontrollable, nuclear-uptake nanodrug delivery system for drug-resistant cancer therapy. Nano Lett 15(1):457–463. doi:10.​1021/​nl503777s PubMedPubMedCentralCrossRef
225.
226.
marketsandmarkets.com (2013) Aptamers market—technology trend analysis by applications—therapeutics, diagnostics, biosensors, drug discovery, biomarker discovery, research applications with market landscape analysis—global forecasts to 2018.
227.
Chen C, Zhou L, Geng J, Ren J, Qu X (2013) Photosensitizer-incorporated quadruplex DNA-gated nanovechicles for light-triggered, targeted dual drug delivery to cancer cells. Small 9(16):2793–2800, 2653. doi:10.​1002/​smll.​201201916
228.
Hattori Y, Maitani Y (2005) Folate-linked lipid-based nanoparticle for targeted gene delivery. Curr Drug Deliv 2(3):243–252PubMedCrossRef
229.
230.
231.
Zuber G, Muller CD, Behr JP (2005) Targeted gene delivery to cancer cells with nanometric DNA particles enveloped with folic acid using a polymerisable anchor. Technol Cancer Res Treat 4(6):637–643PubMedCrossRef
232.
Huang Z, Li H, Huang Q, Chen D, Han J, Wang L, Pan C, Chen W, House MG, Nephew KP, Guo Z (2014) SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer. Mol Carcinog 53(10):777–786. doi:10.​1002/​mc.​22033 PubMedCrossRef
233.
Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardiere C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Muller HH, Skogseid B, Group F-AS (2012) Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 366(23):2189–2197. doi:10.​1056/​NEJMoa1200966 PubMedCrossRef
234.
von Mehren M, Bookman M, Meropol NJ, Weiner LM, Sherman E, Li J, Knoblauch R, Parekh T, Cohen RB (2015) Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies. Cancer Chemother Pharmacol 5(5):1047–1055. doi:10.​1007/​s00280-015-2705-z
235.
Liao L, Liu J, Dreaden EC, Morton SW, Shopsowitz KE, Hammond PT, Johnson JA (2014) A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin. J Am Chem Soc 136(16):5896–5899. doi:10.​1021/​ja502011g PubMedCentralPubMedCrossRef
236.
237.
238.
239.
Li J, Zheng C, Cansiz S, Wu C, Xu J, Cui C, Liu Y, Hou W, Wang Y, Zhang L, Teng IT, Yang HH, Tan W (2015) Self-assembly of DNA nanohydrogels with controllable size and stimuli-responsive property for targeted gene regulation therapy. J Am Chem Soc 137(4):1412–1415. doi:10.​1021/​ja512293f PubMedPubMedCentralCrossRef
240.
Peterson AM, Heemstra JM (2015) Controlling self-assembly of DNA-polymer conjugates for applications in imaging and drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 7(3):282-297. doi:10.​1002/​wnan.​1309
Metadata
Title
Aptamer-Functionalized Nanoparticles as “Smart Bombs”: The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment
Authors
Gregory Benedetto
C. Greer Vestal
Christine Richardson
Publication date
01-12-2015
Publisher
Springer International Publishing
Published in
Targeted Oncology / Issue 4/2015
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-015-0371-z

Other articles of this Issue 4/2015

Targeted Oncology 4/2015 Go to the issue

Original Research

Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo

Day-to-Day Practice

Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor

Review

Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents

Original Research

Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy

Original article

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

Original Research

A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits